Sensei Biotherapeutics’ (SNSE) Buy Rating Reiterated at HC Wainwright

Sensei Biotherapeutics (NASDAQ:SNSE)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They currently have a $4.00 target price on the stock.

Other analysts also recently issued research reports about the stock. Stephens reaffirmed an “overweight” rating and set a $5.00 price objective on shares of Sensei Biotherapeutics in a research report on Friday, May 24th. Citigroup restated a “buy” rating and set a $4.00 price objective on shares of Sensei Biotherapeutics in a report on Monday, June 3rd.

Sensei Biotherapeutics Stock Performance

Sensei Biotherapeutics stock opened at $0.65 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 12.07 and a quick ratio of 12.07. Sensei Biotherapeutics has a 1 year low of $0.51 and a 1 year high of $1.94. The business has a 50 day moving average of $0.67 and a 200-day moving average of $0.91. The company has a market capitalization of $16.30 million, a P/E ratio of -0.54 and a beta of 0.03.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. On average, equities research analysts predict that Sensei Biotherapeutics will post -1.09 earnings per share for the current year.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.